Rogava, Meri
Aprati, Tyler J.
Chi, Wei-Yu http://orcid.org/0000-0002-4617-7827
Melms, Johannes C. http://orcid.org/0000-0002-5410-6586
Hug, Clemens
Davis, Stephanie H.
Earlie, Ethan M. http://orcid.org/0000-0003-3039-9692
Chung, Charlie
Deshmukh, Sachin K.
Wu, Sharon
Sledge, George
Tang, Stephen http://orcid.org/0000-0001-5492-9796
Ho, Patricia
Amin, Amit Dipak http://orcid.org/0000-0002-2613-2082
Caprio, Lindsay
Gurjao, Carino
Tagore, Somnath
Ngo, Bryan
Lee, Michael J.
Zanetti, Giorgia http://orcid.org/0000-0002-3194-0877
Wang, Yiping
Chen, Sean
Ge, William
Melo, Luiza Martins Nascentes
Allies, Gabriele
Rösler, Jonas
Gibney, Goeffrey T.
Schmitz, Oliver J.
Sykes, Megan http://orcid.org/0000-0002-4947-4376
Creusot, Rémi J.
Tüting, Thomas http://orcid.org/0000-0001-7146-0934
Schadendorf, Dirk
Röcken, Martin
Eigentler, Thomas K.
Molotkov, Andrei
Mintz, Akiva
Bakhoum, Samuel F.
Beyaz, Semir http://orcid.org/0000-0003-4730-4012
Cantley, Lewis C. http://orcid.org/0000-0002-1298-7653
Sorger, Peter K. http://orcid.org/0000-0002-3364-1838
Meckelmann, Sven W.
Tasdogan, Alpaslan http://orcid.org/0000-0003-2543-852X
Liu, David http://orcid.org/0000-0003-0346-5033
Laughney, Ashley M. http://orcid.org/0000-0001-9435-953X
Izar, Benjamin http://orcid.org/0000-0003-2379-6702
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA258829)
V Foundation for Cancer Research
Article History
Received: 22 June 2023
Accepted: 8 December 2023
First Online: 29 January 2024
Competing interests
: B.I. has received consulting fees/honoraria from Volastra Therapeutics, Merck, AstraZeneca, Eisai and Janssen Pharmaceuticals and has received research funding to Columbia University from Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore and Synthekine. None of these are relevant to the current work. C.G. has received consulting fees from Watershed Informatics. S.F.B. owns equity in, receives compensation from and serves as a consultant and the Scientific Advisory Board and Board of Directors of Volastra Therapeutics. L.C.C. is a co-founder, member of the scientific advisory board and holds equity in Agios, Petra, Volastra Therapeutics, Faeth and Larkspur. These companies are developing novel therapies for cancer, though drugs from these companies are not discussed in this paper. D.S. reports grants (to institution) from Amgen, Array/Pfizer, Bristol-Myers Squibb, MSD, Novartis and Roche; consulting fees/honoraria from 4SC, Amgen, Array Biopharma, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Haystick, Immunocore, InFlarX, Innocent, LabCorp, Merck Serono, MSD, Nektar, NeraCare, Novartis, OncoSec, Pfizer, Philogen, Pierre Fabre, Replimune, Roche, Sandoz, Sanofi/Regeneron and Sun Pharma; support for attendings meetings or travel support from Bristol-Myers Squibb, MSD, Merck Serono, Novartis, Pierre Fabre and Sanofi; participation on drug safety monitoring or advisory boards for 4SC, Amgen, Array Biopharma, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Immunocore, InFlarX, Merck Serono, MSD, Nektar, NeraCare, Novartis, OncoSec, Pfizer, Philogen, Pierre Fabre, Replimune, Roche, Sandoz, Sanofi/Regeneron and SunPharma; and leadership roles for DeCOG, German Cancer Society, Hiege-Stiftung, Deutsche Hautkrebsstiftung, Nationale Versorgungskonferenz Hautkrebs (NVKH) and European Melanoma Registry (EuMelaReg). S.K.D., S.W. and G.S. are employees of Caris Life Sciences. The other authors declare no competing interests.